Digene attacks cervical screening regimes
This article was originally published in Clinica
About $6 billion is spent on cervical cancer screening in the US every year and women have access to an annual Pap smear. This is at odds with the practice in many other countries, where the screening interval is three to five years.
You may also be interested in...
A new work sharing pilot has been launched to evaluate jointly generic drugs intended for launch in Singapore and Malaysia.
ConMed Corp. is company of two halves ̶ general surgery and orthopedics – and is readying itself for a renewed assault on these two markets on the back of a technology pipeline, targeted acquisitions and a new growth-winning culture, says CFO Todd Garner.